



Maternal and Obstetric Influences on HFpEF during Pregnancy

Carola Edward*

Department of Clinical Pharmacology and Aged Care, Federal University of Sao Paulo, Sao Paulo, Brazil

ABOUT THE STUDY

Pregnancy-associated Heart Failure with preserved Ejection Fraction (HFpEF) is a condition that poses significant risks to both the mother and the fetus. HFpEF occurs when the heart muscle contracts normally but the ventricles do not relax as they should during diastole, leading to inadequate filling of the heart with blood. This condition can be particularly challenging to diagnose and manage during pregnancy due to overlapping symptoms with normal pregnancy physiology and the unique cardiovascular demands placed on the heart during this period.

One of the primary risk factors for developing HFpEF during pregnancy is pre-existing hypertension. Chronic hypertension can lead to structural and functional changes in the heart, including left ventricular hypertrophy and increased stiffness of the heart muscle. These changes can impair the heart's ability to relax and fill properly during diastole, increasing the likelihood of HFpEF. Moreover, hypertensive disorders that develop during pregnancy, such as preeclampsia and gestational hypertension, further exacerbate this risk by introducing acute hemodynamic stresses that can precipitate heart failure.

Obesity is another significant risk factor for pregnancy-associated HFpEF. Excess adipose tissue contributes to a state of chronic inflammation and metabolic dysregulation, which can impair cardiac function. Additionally, obesity is closely linked with other comorbid conditions such as diabetes and hypertension, both of which independently increase the risk of HFpEF. The increased cardiac output required to supply the larger body mass in obese individuals adds further strain on the heart during pregnancy, increasing the potential for heart failure.

Advanced maternal age is also associated with a higher risk of HFpEF during pregnancy. Aging leads to progressive stiffening of the cardiovascular system, including the myocardium and blood vessels. This increased stiffness reduces the compliance of the heart and its ability to accommodate the increased blood volume and cardiac output demands of pregnancy. As the maternal age increases, so does the likelihood of encountering

comorbidities such as hypertension and diabetes, compounding the risk of HFpEF.

Diabetes, both pregestational and gestational, plays a major role in the development of HFpEF during pregnancy. Chronic hyperglycemia results in microvascular and macrovascular complications that affect cardiac function. Diabetic cardiomyopathy, characterized by left ventricular diastolic dysfunction, is a common finding in individuals with diabetes. This dysfunction can be exacerbated during pregnancy due to increased insulin resistance and metabolic demands, increasing the risk of HFpEF.

Cardiomyopathies, particularly hypertrophic and restrictive types, are pre-existing conditions that can predispose pregnant women to HFpEF. These cardiomyopathies are characterized by impaired ventricular filling due to myocardial stiffness or infiltration. The increased blood volume and cardiac output requirements during pregnancy can immense the already weakened heart, leading to heart failure. Proper management of these conditions before and during pregnancy is essential to mitigate the risk of HFpEF.

In addition to maternal factors, there are also obstetric factors that can influence the risk of HFpEF during pregnancy. Multiple gestations, for instance, significantly increase the cardiovascular demands on the mother due to the increased blood volume and cardiac output needed to support more than one fetus. This can strain the heart's ability to relax and fill properly, heightening the risk of HFpEF. Furthermore, complications such as anemia, which is common in multiple pregnancies, can exacerbate cardiac stress and contribute to heart failure.

The presence of structural heart disease, such as congenital heart defects or acquired valvular heart disease also elevates the risk of HFpEF during pregnancy. These conditions can impair the normal function of the heart, making it less capable of handling the increased hemodynamic demands of pregnancy. Close monitoring and management of these conditions are important to prevent the development of HFpEF.

Correspondence to: Carola Edward, Department of Clinical Pharmacology and Aged Care, Federal University of Sao Paulo, Sao Paulo, Brazil, E-mail: carolaward@edu.br

Received: 01-Jul-2024, Manuscript No. CMCH-24-26495; **Editor assigned:** 04-Jul-2024, PreQC No. CMCH-24-26495 (PQ); **Reviewed:** 18-Jul-2024, QC No CMCH-24-26495; **Revised:** 25-Jul-2024, Manuscript No. CMCH-24-26495 (R); **Published:** 01-Aug-2024. DOI: 10.35248/2090-7214.24.21.493.

Citation: Edward C (2024) Maternal and Obstetric Influences on HFpEF during Pregnancy. Clinics Mother Child Health.21.493.

Copyright: © 2024 Edward C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

The implications of HFpEF during pregnancy extend beyond the immediate cardiovascular risks to the mother. Adverse pregnancy outcomes associated with HFpEF include preterm birth, low birth weight, intrauterine growth restriction, and fetal death. The effected cardiac function in the mother can lead to inadequate placental perfusion and oxygen delivery to the fetus, resulting in these adverse outcomes. Additionally, maternal heart failure can necessitate preterm delivery to preserve the health of both the mother and the fetus, contributing to the higher rates of neonatal complications.

Management of pregnancy-associated HFpEF requires a multidisciplinary approach involving cardiologists, obstetricians, and other healthcare providers. Early identification of at-risk individuals through careful screening and monitoring is essential. Treatment strategies should focus on optimizing maternal cardiovascular health, managing comorbid conditions

such as hypertension and diabetes, and closely monitoring fetal well-being. Medications used to treat heart failure must be carefully selected to ensure they are safe for use during pregnancy.

CONCLUSION

In conclusion, HFpEF during pregnancy is a complex condition influenced by various maternal and obstetric risk factors. Understanding these risk factors is major for early identification, prevention, and management to ensure favorable outcomes for both the mother and the fetus. By addressing the modifiable risk factors and providing comprehensive care, healthcare providers can significantly reduce the incidence and impact of HFpEF in pregnant women.